RIGL Rigel Pharmaceuticals
- 13.630
- -0.050-0.37%
- 13.630
- 0.0000.00%
Rigel Pharmaceuticals News
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer RODRIGUEZ RAUL R
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Schorno Dean L
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | EFFECT: Others
Rigel Pharmaceuticals | CORRESP: CORRESP
Rigel Pharmaceuticals | UPLOAD: Others
Rigel Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Rigel Pharmaceuticals | 8-K: Press Release, dated August 6, 2024, titled “Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update.”
Rigel Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Rigel Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Wasman Jane
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MOOS WALTER H
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director LAPOINTE ANTHONY GREGG
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Kotzin Brian L.
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director HANNAH ALISON L.
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Ali-Jackson Kamil
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | 10-Q: Q1 2024 Earnings Report
Analysis
Price Target
No Data
No Data